Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED90 of remimazolam + alfentanil for inhibiting gastroscope insertion reactions in obese patients
ChiCTR2600122945Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam and alfentanil in anxiety disorder and None (2 arms), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: ED50. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
remimazolamalfentanil
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on ChiCTR2600122945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122945.